AHMEDABAD: Major homegrown pharmaceutical company Torrent Pharmaceuticals Limited announced on Wednesday that it has entered into a strategic alliance with Boehringer Ingelheim India Private Limited (BI India) to jointly market its anti-diabetic medicines in the Indian market. These include cospiaq (Empagliflozin) and Cospiaq MetTM (Empagliflozin + Metformin) and Xilingian (Empagliflozin and Linagliptin).
Empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, is used to improve glycemic control in adults with type 2 diabetes. It is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes. and established cardiovascular disease. It is also prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.
According to AWACS MAT data of November 2022, the Indian diabetes drug market is valued at Rs 16,672 crore.
Aman Mehtadirector, torrent pharmasaid: "The launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and reinforce our position as a leading player in these high-growth segments within the Indian pharmaceutical market."
Empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, is used to improve glycemic control in adults with type 2 diabetes. It is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes. and established cardiovascular disease. It is also prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.
According to AWACS MAT data of November 2022, the Indian diabetes drug market is valued at Rs 16,672 crore.
Aman Mehtadirector, torrent pharmasaid: "The launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and reinforce our position as a leading player in these high-growth segments within the Indian pharmaceutical market."
